Attorneys for the plaintiff and drugmaker McNeil Consumer Healthcare went back and forth Tuesday in federal court over motions to exclude pieces of evidence—some related to profit margins and lobbying—in the first bellwether trial in the Philadelphia-based Tylenol multidistrict litigation.
Argument in the case took place during a status conference before U.S. District Judge Lawrence F. Stengel of the Eastern District of Pennsylvania. The conference came days after a series of rulings from Stengel denying McNeil’s requests to toss the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
